10x Genomics Inc.
TXG | NASDAQ
$81.70
+$2.60 (+3.29%)
Sep 22, 2026, 1:11 PM ET · Market open
Company Profile
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Key Executives
| Name | Position |
|---|---|
| Serge Saxonov | Co-Founder, Chief Executive Officer & Director |
| Adam S. Taich | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer |
| Michael Schnall-Levin | Founding Scientist & Chief Technology Officer |
| Benjamin J. Hindson | Co-Founder, President, Chief Scientific Officer & Director |
| Cassie Corneau | Manager of Investor Relations & Strategic Finance |
| Jens Durruthy | Associate Director of Product Management |
| Jim Goodrich | Chief of Global Operations |
| Mennah Moustafa | Chief Commercial Officer |
| Randy Wu | General Counsel and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 26, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 4 | Filing |
10x Genomics Inc.
| Country | United States |
| IPO Date | Sep 11, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,178 |
| CEO | Serge Saxonov |
Contact Details
6230 Stoneridge Mall Road Pleasanton,
California 94588-3260 United States
Stock Details
| Ticker Symbol | TXG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001770787 |
| CUSIP Number | 88025U109 |
| ISIN Number | US88025U1097 |
| SIC Code | 3826 |
Recent News
- 22 hours ago / gurufocus.com10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors
- 12 days ago / prnewswire.comLunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
- 14 days ago / gurufocus.com10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100
- 19 days ago / zacks.com10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
- 22 days ago / zacks.comTXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
- 1 month ago / seekingalpha.com10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)
- 2 months ago / zacks.com10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
- 2 months ago / marketbeat.com10x Genomics Q2 Earnings Call Highlights
- 2 months ago / seekingalpha.com10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.com10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Add to Watchlist
Select watchlists to add or remove TXG